The real GLP-1 cost crisis 

Short-term use. Long-term costs. The fix? Behavior-first strategies that last.  

Here’s the truth: 30% of people discontinue GLP-1s within their first four weeks, and over half stop within the first year. That early exit doesn’t just stall progress — it reignites risk and sends costs into overdrive.   

This lightpaper reveals the real GLP-1 cost crisis: short-term use. And it shows how a behavior-first approach can protect your investment, deliver sustainable outcomes, and finally unlock the ROI you’ve been promised. 

Here’s what we unpack: 

• Why most GLP-1 strategies miss the mark

• What happens when employees stop taking them

• The root causes GLP-1s don’t touch — like systemic chronic inflammation

• How behavior change unlocks lasting health - and real savings 

GLP-1s treat symptoms. Behavior change treats the cause. 

Download the lightpaper. Rethink your strategy. Make healthiness happen.